The use of the CD33 transmembrane glycoprotein for targeted therapy delivery in AML was prompted by earlier studies showing higher CD33 expression level in AML leukemic blasts, as compared to normal myeloid cells [4]. Here, CD33 is linked to acute myeloid leukemia.